复方鳖甲软肝片联合丁二磺酸腺苷蛋氨酸和熊去氧胆酸治疗PBC患者疗效及其对血清肝纤维化指标的影响*

doi:10.3969/j.issn.1672-5069.2018.03.006

摘要/Abstract

摘要： 目的探讨复方鳖甲软肝片联合丁二磺酸腺苷蛋氨酸肠溶片和熊去氧胆酸胶囊治疗原发性胆汁性肝硬化（PBC）患者的疗效及对血清肝纤维化指标的影响。方法 2012年9月~2016年9月我院诊治的64例PBC患者,采用随机数字表法将其分为观察组32例和对照组32例。给予对照组丁二磺酸腺苷蛋氨酸和熊去氧胆酸胶囊治疗,观察组在对照组治疗的基础上给予复方鳖甲软肝片治疗,两组均治疗24 w。采用放射免疫法检测血清透明质酸（HA）、三型前胶原N端肽（PC-III）、四型胶原（IV-C）和层粘连蛋白（LN）水平,采用GQOL-74生活质量评分量表行生活质量评价。结果在治疗24 w末,观察组血清ALT、AST和TBIL水平分别为（54.4±15.0） U/L、（61.3±16.4） U/L和（23.7±9.5） μmol/L,明显低于对照组[分别为（70.3±16.1） U/L、（75.5±16.5） U/L和（36.8±9.7）μmol/L,P<0.05];观察组血清HA、LN、PC-III和IV-C水平分别为（116.9±12.5） μg/L、（103.4±11.4）μg/L、（123.6±22.8） μg/L和（80.4±9.8）μg/L,明显低于对照组[（156.5±12.7） μg/L、（126.9±11.2） μg/L、（155.5±22.4）μg/L和（97.6±9.9）μg/L,P<0.05];观察组躯体功能、心理功能、社会功能和物质生活评分分别为（78.9±8.6）分、（80.8±7.5）分、（89.7±9.7）分和（83.7±9.3）分,明显高于对照组[（69.7±8.3）分、（71.9±7.6）分、（79.7±9.5）分和（75.2±9.2）分,P<0.05]。结论复方鳖甲软肝片联合丁二磺酸腺苷蛋氨酸肠溶片和熊去氧胆酸胶囊治疗PBC患者效果显著,可有效改善患者肝功能,降低血清HA、LN、PC-III和IV-C水平,提高患者生活质量。

关键词: 原发性胆汁性肝硬化, 复方鳖甲软肝片, 丁二磺酸腺苷蛋氨酸, 熊去氧胆酸, 治疗

Abstract: Objective To investigate the efficacy of Fufangbiejia Ruanganpian,a herbal compound, and ursodeoxycholic acid（UDCA） combination in the treatment of patients with primary biliary cirrhosis （PBC）. Methods 64 patients with PBC were recruited in this study between September 2012 and September 2016,and they were randomly divided into two groups by computer-generated numbers. The patients in observation group received Fufangbiejia Ruanganpian,succinic acid adenosine methionine,and UDCA,and the patients in the control received all but the herbal compound medicines. Serum hyaluronic acid（HA）,laminin（LN）,procollagen Ⅲ N terminal peptide（PC-III） and type fore collagen（IV-C） levels were detected routinely and life quality was estimated by GQOL-74. Results At the end of observation,serum ALT,AST and TBIL levels in the combination group were（54.4±15.） U/L,（61.3±16.4） U/L and （23.7±9.5） μmol/L,significantly lower than （70.3±16.1） U/L,（75.5±16.5） U/L and（36.8±9.7） μmol/L in the control（P<0.05）;serum HA,LN,PC-III and IV-C levels were （116.9±12.5） μg/L,（103.4±11.4） μg/L,（123.6±22.8） μg/L and （80.4±9.8）μg/L,significantly lower than （156.5±12.7）μg/L,（126.9±11.2） μg/L,（155.5±22.4）μg/L and（97.6±9.9）μg/L in the control（P<0.05）;the physical function, psychological function,social function and material life scores were（78.9±8.6）,（80.8±7.5）,（89.7±9.7） and （83.7±9.3）, significantly higher than（69.7±8.3）,（71.9±7.6）,（79.7±9.5） and（75.2±9.2） in the control（P<0.05）. Conclusion The combination of the Chinese herbal compound and adenosine methionine as well as UDCA in treatment of patients with PBC is effective,which might improve the liver functions,reduce serum HA,LN,PC-III and IV-C levels,and improve the quality of life.

Key words: Primary biliary cirrhosis, Fufangbiejia Ruanganpian, a herbal medicine, Metionine, Ursodeoxycholic acid, Therapy

刘进国, 王暴魁. 复方鳖甲软肝片联合丁二磺酸腺苷蛋氨酸和熊去氧胆酸治疗PBC患者疗效及其对血清肝纤维化指标的影响*[J]. 实用肝脏病杂志, 2018, 21(3): 340-343.

Liu Jinguo, Wang Baokui. Efficacy of Fufangbiejia Ruanganpian and ursodeoxycholic acid combination in the treatment of patients with primary biliary cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 340-343.

参考文献

[1] Beuers U,Gershwin ME,Gish RG,et al.Changing nomenclature for PBC:From‘cirrhosis’ to ‘cholangitis’. Gut,2015,64(11):1671-1672.
[2] Carey EJ,Ali AH,Lindor KD.Primary biliary cirrhosis. Lancet,2015,386(10003):1565-1575.
[3] Liu H,Liu Y,Wang L,et al.Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol,2010,4(10):100-103.
[4] Victoria G,Anita L,Vgren S,et al.The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid. PLoS One,2014,9(1):e83-828.
[6] Hirschfield GM.Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol,2011,25(6):701-712.
[7] 张作记. 行为医学量表手册. 北京: 中华医学电子音像出版社,2001:131-132.
[8] Silveira MG,Burnt EM,Heathcote J,et al.American associationfor the study of liver diseases endpoints conference:design and endpoints for clinical trials in primary biliary cirrhosis. J Hepatol,2010,25(1):349-359.
[9] Griffiths L,Dyson JK,Jones DE.The new epidemiology of primary biliary cirrhosis. Semin Liver Dis,2014,34(3):318-328.
[10] Poupon R.Ursodeoxycholic acid and bile-acid mimetics astherapeutic agents for cholestatic liver diseases:an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol,2012,36(Suppl 1):S3-S12.
[11] Rautiainen H,Karkkainen P,Karvonen AL,et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three -year randomized trial. Hepatology,2005,41(4):747-752.
[12] Dempster DW,Lambing CL,Kostenuik PJ,et al.Role of RANK ligand and denosumab,a targeted RANK ligand inhibitor,in bone health and osteoporosis:a review of preclinical and clinical data. Clin Ther,2012,34:521-536.
[13] Mason AL,Lindor KD,Bacon BR,et al.Clinical trial: Randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther,2008,28(7):886-894.
[14] Leung J,Bonis PA,Kaplan MM.Colchicine or methotrexate,with ursodiol,are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol,2011,9(9):776-780.
[15] Lyu JL,Jin SY,Yuan HL,et al.Rational daily administration times of Yinchenhao decoction in rats with jaundice based on PD/PK. Chin Herbal Med,2012,4(2):150.
[17] Appourchaux K,Dokmak S,Resche-Rigon M,et al.MicroRNA-based diagnostic tools foradvanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep,2016,6:34935.
[18] 孔祥璐,郭晓霞. 中药联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化疗效系统评价. 实用肝脏病杂志,2015,18(4):379-382.
[19] Angulo P,Jorgensen RA,Keach JC,et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology,2000,31(2):318-323.
[20] Hu Q,Noor M,Wong YF,et al.In vitro anti-fibrotic activities of herbal compounds and herbs. Nephrol Dial Transplant,2009,24(10):3033-3041.

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[6]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[7]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[8]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[9]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[10]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[11]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[12]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[13]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[14]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[15]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.